Verrica Pharmaceuticals (VRCA) Stock Forecast, Price Target & Predictions
VRCA Stock Forecast
Verrica Pharmaceuticals stock forecast is as follows: an average price target of $12.00 (represents a 509.14% upside from VRCA’s last price of $1.97) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
VRCA Price Target
The average price target for Verrica Pharmaceuticals (VRCA) is $12.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $10.00. This represents a potential 509.14% upside from VRCA's last price of $1.97.
VRCA Analyst Ratings
According to 4 Wall Street analysts, Verrica Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for VRCA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Verrica Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Glen Santangelo | Jefferies | $12.00 | $11.28 | 6.37% | 509.14% |
| May 14, 2024 | Oren Livnat | H.C. Wainwright | $14.00 | $9.56 | 46.44% | 610.66% |
| Jul 25, 2023 | Serge Belanger | Needham | $10.00 | $5.32 | 87.97% | 407.61% |
The latest Verrica Pharmaceuticals stock forecast, released on May 14, 2024 by Glen Santangelo from Jefferies, set a price target of $12.00, which represents a 6.37% increase from the stock price at the time of the forecast ($11.28), and a 509.14% increase from VRCA last price ($1.97).
Verrica Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $13.00 |
| Last Closing Price | $1.97 | $1.97 | $1.97 |
| Upside/Downside | -100.00% | -100.00% | 559.90% |
In the current month, the average price target of Verrica Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verrica Pharmaceuticals's last price of $1.97. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 14, 2024 | Jefferies | Buy | Buy | Hold |
| May 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 25, 2023 | Needham | - | Buy | Upgrade |
| Feb 13, 2023 | RBC Capital | Sector Perform | Outperform | Upgrade |
| May 25, 2022 | RBC Capital | - | Sector Perform | Downgrade |
Verrica Pharmaceuticals's last stock rating was published by Jefferies on May 14, 2024. The company gave VRCA a "Buy" rating, the same as its previous rate.
Verrica Pharmaceuticals Financial Forecast
Verrica Pharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $1.99M | $2.92M | $182.00K | $37.00K | $68.00K | $8.32M | - | $431.00K | - | $12.00M |
| Avg Forecast | $7.86M | $6.21M | $4.58M | $2.81M | $975.25K | $454.07K | $57.60K | $322.00K | $312.50K | $4.33M | $312.50K | $332.40K | $200.00K | $20.37M |
| High Forecast | $9.60M | $6.47M | $5.60M | $3.43M | $1.24M | $554.71K | $70.37K | $393.37K | $381.76K | $5.29M | $312.50K | $401.36K | $241.49K | $24.44M |
| Low Forecast | $5.81M | $5.80M | $3.39M | $2.07M | $700.41K | $335.48K | $42.56K | $237.90K | $230.88K | $3.20M | $312.50K | $261.59K | $157.39K | $16.29M |
| # Analysts | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 8 | 5 | 11 |
| Surprise % | - | - | - | - | 2.04% | 6.42% | 3.16% | 0.11% | 0.22% | 1.92% | - | 1.30% | - | 0.59% |
Verrica Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $2.81M, with a low forecast of $2.07M, and a high forecast of $3.43M. VRCA's average Quarter revenue forecast represents a 41.21% increase compared to the company's last Quarter revenue of $1.99M (Dec 23).
Verrica Pharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 8 | 5 | 11 |
| EBITDA | - | - | - | - | $-27.81M | $-23.92M | $-11.62M | $-6.46M | $-5.93M | $1.73M | - | $-7.29M | $-10.66M | $103.00K |
| Avg Forecast | $-1.57M | $-1.24M | $-916.63K | $-561.45K | $-195.05K | $-90.81K | $-11.52K | $-64.40K | $-62.50K | $-865.95K | $-62.50K | $-9.74M | $-11.77M | $174.81K |
| High Forecast | $-1.16M | $-1.16M | $-677.23K | $-414.82K | $-140.08K | $-67.09K | $-8.51K | $-47.58K | $-46.18K | $-639.79K | $-62.50K | $-7.79M | $-9.42M | $209.77K |
| Low Forecast | $-1.92M | $-1.29M | $-1.12M | $-685.90K | $-248.25K | $-110.94K | $-14.07K | $-78.67K | $-76.35K | $-1.06M | $-62.50K | $-11.68M | $-14.13M | $139.84K |
| Surprise % | - | - | - | - | 142.58% | 263.37% | 1008.42% | 100.28% | 94.91% | -2.00% | - | 0.75% | 0.91% | 0.59% |
1 analysts predict VRCA's average Quarter EBITDA for Dec 22 to be $-62.50K, with a high of $-46.18K and a low of $-76.35K. This is -103.62% lower than Verrica Pharmaceuticals's previous annual EBITDA (Sep 22) of $1.73M.
Verrica Pharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 8 | 5 | 11 |
| Net Income | - | - | - | - | $-25.11M | $-24.80M | $-10.99M | $-6.09M | $-5.65M | $-1.28M | - | $-9.53M | $-11.78M | $-936.00K |
| Avg Forecast | $-16.56M | $-17.87M | $-19.24M | $-20.78M | $-26.13M | $-16.80M | $-9.77M | $-8.86M | $-8.90M | $-4.88M | $-14.87M | $-11.35M | $-13.00M | $-1.59M |
| High Forecast | $-10.94M | $-16.38M | $-12.71M | $-13.73M | $-23.91M | $-11.10M | $-6.45M | $-5.85M | $-5.88M | $-3.22M | $-14.87M | $-9.08M | $-10.40M | $-1.27M |
| Low Forecast | $-21.33M | $-19.36M | $-24.79M | $-26.77M | $-28.36M | $-21.64M | $-12.59M | $-11.41M | $-11.46M | $-6.29M | $-14.87M | $-13.62M | $-15.60M | $-1.91M |
| Surprise % | - | - | - | - | 0.96% | 1.48% | 1.12% | 0.69% | 0.64% | 0.26% | - | 0.84% | 0.91% | 0.59% |
Verrica Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VRCA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Verrica Pharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 8 | 5 | 11 |
| SG&A | - | - | - | - | $17.00M | $20.05M | $5.94M | $4.32M | $3.19M | $3.92M | - | $5.12M | $7.28M | $6.58M |
| Avg Forecast | $24.09M | $19.04M | $14.05M | $8.60M | $2.99M | $1.39M | $176.55K | $986.98K | $957.86K | $13.27M | $957.86K | $1.02M | $613.03K | $11.16M |
| High Forecast | $29.43M | $19.84M | $17.16M | $10.51M | $3.80M | $1.70M | $215.69K | $1.21M | $1.17M | $16.21M | $957.86K | $1.23M | $740.22K | $13.40M |
| Low Forecast | $17.80M | $17.77M | $10.38M | $6.36M | $2.15M | $1.03M | $130.44K | $729.21K | $707.69K | $9.81M | $957.86K | $801.80K | $482.43K | $8.93M |
| Surprise % | - | - | - | - | 5.69% | 14.41% | 33.63% | 4.38% | 3.33% | 0.30% | - | 5.02% | 11.88% | 0.59% |
Verrica Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $8.60M, based on 1 Wall Street analysts, with a range of $6.36M to $10.51M. The forecast indicates a -49.37% fall compared to VRCA last annual SG&A of $17.00M (Dec 23).
Verrica Pharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 8 | 5 | 11 |
| EPS | - | - | - | - | $-0.00 | $-0.00 | $-0.00 | $-0.14 | $-0.14 | $-0.03 | - | $-0.35 | $-0.43 | $-0.04 |
| Avg Forecast | $-0.36 | $-0.38 | $-0.41 | $-0.45 | $-0.56 | $-0.36 | $-0.21 | $-0.19 | $-0.19 | $-0.10 | $-0.32 | $-0.33 | $-0.41 | $-0.35 |
| High Forecast | $-0.24 | $-0.35 | $-0.27 | $-0.30 | $-0.51 | $-0.24 | $-0.14 | $-0.13 | $-0.13 | $-0.07 | $-0.32 | $-0.24 | $-0.30 | $-0.25 |
| Low Forecast | $-0.46 | $-0.42 | $-0.53 | $-0.58 | $-0.61 | $-0.47 | $-0.27 | $-0.25 | $-0.25 | $-0.14 | $-0.32 | $-0.42 | $-0.53 | $-0.44 |
| Surprise % | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.74% | 0.73% | 0.30% | - | 1.05% | 1.04% | 0.12% |
According to undefined Wall Street analysts, Verrica Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VRCA previous annual EPS of $NaN (undefined).
Verrica Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.24 | $36.00 | 1507.14% | Buy |
| VRCA | Verrica Pharmaceuticals | $1.97 | $12.00 | 509.14% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| VIGL | Vigil Neuroscience | $3.67 | $11.00 | 199.73% | Buy |
| ARQT | Arcutis Biotherapeutics | $10.66 | $31.00 | 190.81% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| ETON | Eton Pharmaceuticals | $5.15 | $8.50 | 65.05% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| CNTB | Connect Biopharma | $1.23 | $1.50 | 21.95% | Buy |
| VRNA | Verona Pharma | $29.78 | $33.00 | 10.81% | Buy |
| KDNY | Chinook Therapeutics | $40.39 | $30.00 | -25.72% | Buy |
VRCA Forecast FAQ
Is Verrica Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, Verrica Pharmaceuticals (VRCA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of VRCA's total ratings.
What is VRCA's price target?
Verrica Pharmaceuticals (VRCA) average price target is $12 with a range of $10 to $14, implying a 509.14% from its last price of $1.97. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Verrica Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for VRCA stock, the company can go up by 509.14% (from the last price of $1.97 to the average price target of $12), up by 610.66% based on the highest stock price target, and up by 407.61% based on the lowest stock price target.
Can Verrica Pharmaceuticals stock reach $3?
VRCA's average twelve months analyst stock price target of $12 supports the claim that Verrica Pharmaceuticals can reach $3 in the near future.
What are Verrica Pharmaceuticals's analysts' financial forecasts?
VRCA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $21.46M (high $25.1M, low $17.06M), average EBITDA is $-4.292M (high $-3.413M, low $-5.02M), average net income is $-74.458M (high $-53.756M, low $-92.253M), average SG&A $65.78M (high $76.94M, low $52.3M), and average EPS is $-1.601 (high $-1.156, low $-1.984).
Did the VRCA's actual financial results beat the analysts' financial forecasts?
Based on Verrica Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $5.12M, beating the average analysts forecast of $1.81M by 183.26%. Apple's EBITDA was $-65.759M, beating the average prediction of $-362K by 18076.52%. The company's net income was $-66.995M, beating the average estimation of $-61.568M by 8.82%. Apple's SG&A was $47.3M, beating the average forecast of $5.54M by 753.17%. Lastly, the company's EPS was $-0.0015, missing the average prediction of $-1.324 by -99.89%. In terms of the last quarterly report (Dec 2023), Verrica Pharmaceuticals's revenue was $1.99M, beating the average analysts' forecast of $975.25K by 103.85%. The company's EBITDA was $-27.811M, beating the average prediction of $-195K by 14158.47%. Verrica Pharmaceuticals's net income was $-25.114M, missing the average estimation of $-26.134M by -3.90%. The company's SG&A was $17M, beating the average forecast of $2.99M by 468.53%. Lastly, the company's EPS was $-0.0006, missing the average prediction of $-0.562 by -99.89%